AstraZeneca dual immunotherapy approved for US liver cancer patients
The FDA has approved Imfinzi™ combined with Imjudo for adults with unresectable liver cancer, based on a lower risk of death compared to only sorafenib.
List view / Grid view
The FDA has approved Imfinzi™ combined with Imjudo for adults with unresectable liver cancer, based on a lower risk of death compared to only sorafenib.
COVID-19 vaccine key players back a new proposal ensuring vaccines for future pandemics are equally distributed to all priority populations.
£2 million will help fund a UK team of scientific experts to research monkeypox, uncover novel treatments and curb the spread of the virus.
COVID-19 has accelerated the decline in late-stage industry clinical research in the UK, compared to its global peers.
Clinical trial results suggest adult HIV patients can be protected against hepatitis B with a three-dose vaccine series.
A collaboration agreement between Gilead and biopharma company MacroGenics aims to develop MGD024, a bispecific antibody for treatment of blood cancers.
Shingrix can effectively vaccinate adults over 50 years old against shingles for at least 10 years, new data shows.
City of Hope has developed AOH1996, a promising cancer medicine, for people with reoccurring solid tumours.
Apogenix’s asunercept demonstrates efficacy in Phase II trial for the treatment of hospitalised COVID-19 patients.
NIIMBL and BioPhorum reveal open-access design models for a new buffer stock blending system that could help reduce bottlenecks in biomanufacturing plants.
The first oral contraceptive tablet using a combination of estetrol (E4) and drospirenone (DRSP) is available in the UK.
Eli Lilly and Company’s $610 million acquisition of Akouos will fast-track gene therapies that restore, improve and preserve hearing for patients worldwide.
Research for rare diseases including ALS will be supported over the next four years by $38 million in FDA funding.
Near-term gains from outsourcing biopharma R&D activities can be offset by slower innovation in the long run, according to a recent paper.
Yescarta approved by EC for the treatment of large B-Cell lypmphoma and high grade B-cell lymphoma.